Introduction 44 45
Epilepsy affects over 60 million people worldwide (Ngugi et al., 2010) . Even with optimal treatment 46 approximately 30% remain resistant to pharmacotherapy (Kwan et al., 2011; Picot et al., 2008) . The 47 development of new anti-epileptic drugs in the last 20 years has had little impact on refractory 48 epilepsy; people with inadequately controlled seizures continue to experience major co-morbidities, 49 social exclusion, and an annual rate of sudden unexpected death in epilepsy (SUDEP) of 0.5-1% 50 (Devinsky, 2011; Hoppe and Elger, 2011) . Although surgical resection of the epileptogenic zone can 51 result in seizure freedom, it is unsuitable for over 90% of refractory epilepsy patients (Lhatoo et prominent, but discrete seizures lasting over 20 seconds are rare. Lentiviral overexpression of the 80 human potassium channel Kv1.1, encoded by KCNA1, was highly effective at reducing pathological 81 high frequency activity (Wykes et al., 2012 We first asked whether the CMV-driven KCNA1 lentivector (CMV-KCNA1) used previously in a model 116 of EPC (Wykes et al., 2012) was also effective in an epilepsy model characterized by discrete 117 seizures. Epilepsy ( Fig. 1A ; Supp. were delivered directly into the seizure focus and followed by a further 4 weeks of ECoG recording 126 (Fig. 1B) . 127
128
The CMV-KCNA1 lentivector transduced neurons within a narrow column of the cortex (Fig. 1C) . As is 129 typical of this model (Chang et al., 2018) , the total number of seizures experienced by each animal 130 over the 6 weeks of recording was highly variable (Fig. 1D) . Consequently, to compare seizure 131 frequency between the two treatment groups the numbers of seizures experienced each week were 132 normalized to the number experienced in the week preceding treatment (week −1, or baseline (Bl) 133 week). Despite the small sample size (6 treated vs. 5 controls), the CMV-KCNA1 lentivector 134 significantly reduced normalized seizure frequency compared to controls in the weeks following 135 treatment (generalized log-linear mixed model on weeks 0 -3, treatment*week interaction effect: 136 F(1,40) = 4.851, p = 0.033; Fig. 1E ). The therapeutic effect emerged rapidly; plots of normalized 137 cumulative daily seizure frequency for the two groups diverged within 3 days of lentivector injection, 138 consistent with rapid transgene expression, as seen previously in the motor cortex model (Fig. 1F) . 139
140
This pilot study strongly suggests that KCNA1 gene therapy can suppress spontaneous discrete 141 seizures. However, the CMV-KCNA1 lentivector tested is poorly suited for clinical translation. We 142 therefore set out to develop an optimized vector with improved safety and efficacy. 143
144

Design and characterization of an EKC gene therapy optimized for clinical translation 145
The transfer plasmid used to synthesize the optimized lentivector differed from the original CMV-147 KCNA1 construct in several ways ( Fig. 2A) . The non-cell type specific CMV promoter was replaced 148 with a 1.3 kb human CAMK2A promoter to bias expression to excitatory neurons (Dittgen et (Fig. 2B) . To test the therapeutic efficacy of the EKC lentivector, we designed a blinded, randomized, placebo-174 controlled pre-clinical trial, and selected normalized seizure frequency as the primary outcome 175 measure. Eleven days after injection of TeNT into the visual cortex, 26 rats were randomized into 176 two groups and injected via a pre-implanted cannula with either the EKC lentivector or its dscGFP-177 only control. ECoG recordings were continued for a further 4 weeks. The timeline was altered from 178 that of the pilot study to treat after 11 days in order to capture the period when seizure activity is at 179 its highest (2 -4 weeks following TeNT injection) (Fig. 3A) . 180
181
To minimize the confounding influence of animals that displayed a very low seizure frequency prior 182 to treatment, subjects were excluded if they exhibited fewer than five seizures in the week 183 preceding lentiviral delivery (the baseline week). This criterion, applied before unblinding, led to the 184 exclusion of eight animals (6 EKC, 2 control). Of the remaining 18, all but one survived for the 185 duration of recording. This rat (from the EKC group) was culled in the final week due to detachment 186 of its headpiece. However, because the subject had already passed through the period of peak 187 seizure activity, and in order to maximise the amount of data obtained from the study, this 188 incomplete dataset was included in the overall analysis. Again, this decision was made before 189 unblinding. We have previously shown that overexpression of Kv1.1 can reduce the frequency of brief (< 1 s), 210
high-frequency epileptiform discharges in a motor cortex TeNT model of EPC (Wykes et al., 2012) . 211
However, this study did not investigate whether Kv1.1 overexpression could inhibit discrete seizures 212 lasting 1 -2 minutes, more typical of common forms of focal epilepsy. We show here, in two 213 independent trials, that Kv1.1 overexpression is indeed sufficient to reduce the frequency of 214 seizures, although interestingly seizure duration was not altered. This is most simply explained by 215
proposing that seizure initiation is rapidly accompanied by propagation to other brain areas, beyond 216 the lentivector-treated region, consistent with the convulsions seen in the majority of seizures in the 217 visual cortex TeNT model (Chang et al., 2018) . single Boltzmann function (Fig. 2Biii) . 305
306
Lentiviral synthesis 307 The CMV-KCNA1 lentivector was identical to that used in Wykes et al., 2012 (Wykes et al., 2012). For 308
the EKC lentivector and its dscGFP-only control, HEK293T producer cells were grown in Gibco® 309 DMEM + GlutaMAX™ supplemented with 10% heat-inactivated foetal bovine serum and 1% 310 penicillin/streptomycin. Cultures were maintained in logarithmic growth phase in a humidified 5% 311 CO 2 atmosphere at 37°C. Cells were split every 3 -4 days using 0.05% Trypsin-EDTA (Thermo Fisher 312 Scientific) and never grown for more than 15 passages. Cells were co-transfected with pMDG-VSV.G, 313 pCMVdR8.74 D64V and either the EKC transfer plasmid or its dscGFP-only control. The mass ratio of 314 envelope to packaging to transfer plasmids was 1 : 2.5 : 1.5. Transfections were performed according 315 to the manufacturer's instructions using Lipofectamine® 2000 (Thermo Fisher Scientific). The 316 transfection medium was replaced after 18 hours. Two media harvests were collected, at 40 hours 317 and 60 hours after transfection. Harvested media were pre-cleaned by centrifugation at 1000 rpm 318 for 3 minutes at 4 C and filtered through 0.45 m micropores. Media were overlaid on a sucrose 319 solution with the following composition (in mM): 50 Tris-HCl, 100 NaCl, 0.5 EDTA (pH 7.4, 10% w/v 320 sucrose), and centrifuged at 20,000 rpm for 2 hours at 4 C. Lentiviral pellets were resuspended in 321 sterile PBS, aliquoted, snap-frozen and stored at −80 C. Viral titre was approximated using the Lenti-322 X™ p24 rapid titer kit (Clontech). Each titration was performed in triplicate with 3 separate aliquots. 323 Estimated titres were 2.42 × 10 9 IU/ml (EKC lentivector) and 4.26 × 10 9 IU/ml (dscGFP-only control). 324
Surgical procedures 326
All experiments were performed in accordance with the United Kingdom Animals (Scientific 327 Brains were removed and post-fixed in 4% PFA at 4 C for a further 24 hours. After washing in PBS 357 brains were sliced into 70 m coronal sections using a vibrating microtome (Leica) and stored free-358 floating at 4 C in PBS plus 0.02% sodium azide (Sigma). For antibody staining, slices were 359 permeabilized for 20 minutes in PBS plus 0.3% Triton X-100 (Sigma) before blocking for 1 hour in PBS 360 plus 0.3% Triton X-100, 1% bovine serum albumin (Sigma) and 4% goat serum (Sigma) Data from the pilot study were used to determine sample sizes for the final pre-clinical trial. We 380 estimated that the maximal weekly seizure frequency would double from baseline, and we wished to 381 detect with 80% power a 40% reduction from this maximum at p < 0.05. Given a mean baseline 382 weekly seizure frequency of 5 or above, a modification of Lehr's formula (Lehr, 1992) for the Poisson 383 distribution suggested 7 -8 animals per group would be sufficient to detect a reduction in seizure 384 frequency from 10 to 6 per week. Our modified Lehr's formula is given by the following equation: 385
where n is the size of each sample (treatment group), λ 1 the mean weekly seizure frequency before 388 treatment, and λ 2 the mean weekly seizure frequency after treatment. 389 390 Efficacy of treatment data (Fig. 1E, 3B ) were analysed using a generalized log-linear mixed model 391 with random effect of animal (autoregressive covariance) and fixed effects of treatment group, 392 week, and the interaction between treatment group and week. Seizure counts in the week preceding 393 treatment were compared using a Mann Whitney U test. Current densities at +20 mV (Fig. 2Bii) were 394 compared using a Welch's one-way ANOVA followed by Games-Howell post-hoc tests. 
